Show simple item record

AuthorErnst, Katharinadc.contributor.author
Date of accession2022-06-23T12:09:46Zdc.date.accessioned
Available in OPARU since2022-06-23T12:09:46Zdc.date.available
Date of first publication2022-03-03dc.date.issued
AbstractPertussis, also known as whooping cough, is a respiratory disease caused by infection with Bordetella pertussis, which releases several virulence factors, including the AB-type pertussis toxin (PT). The characteristic symptom is severe, long-lasting paroxysmal coughing. Especially in newborns and infants, pertussis symptoms, such as leukocytosis, can become life-threatening. Despite an available vaccination, increasing case numbers have been reported worldwide, including Western countries such as Germany and the USA. Antibiotic treatment is available and important to prevent further transmission. However, antibiotics only reduce symptoms if administered in early stages, which rarely occurs due to a late diagnosis. Thus, no causative treatments against symptoms of whooping cough are currently available. The AB-type protein toxin PT is a main virulence factor and consists of a binding subunit that facilitates transport of an enzyme subunit into the cytosol of target cells. There, the enzyme subunit ADP-ribosylates inhibitory α-subunits of G-protein coupled receptors resulting in disturbed cAMP signaling. As an important virulence factor associated with severe symptoms, such as leukocytosis, and poor outcomes, PT represents an attractive drug target to develop novel therapeutic strategies. In this review, chaperone inhibitors, human peptides, small molecule inhibitors, and humanized antibodies are discussed as novel strategies to inhibit PT.dc.description.abstract
Languageendc.language.iso
PublisherUniversität Ulmdc.publisher
LicenseCC BY 4.0 Internationaldc.rights
Link to license texthttps://creativecommons.org/licenses/by/4.0/dc.rights.uri
Keywordnovel inhibitorsdc.subject
Keywordchaperonesdc.subject
Keywordhumanized antibodiesdc.subject
Keywordhuman defensinsdc.subject
KeywordADP-ribosylation inhibitordc.subject
Dewey Decimal GroupDDC 570 / Life sciencesdc.subject.ddc
Dewey Decimal GroupDDC 610 / Medicine & healthdc.subject.ddc
LCSHPertussis toxindc.subject.lcsh
LCSHMolecular chaperonesdc.subject.lcsh
LCSHADP-ribosylationdc.subject.lcsh
TitleNovel strategies to inhibit pertussis toxindc.title
Resource typeWissenschaftlicher Artikeldc.type
SWORD Date2022-04-08T09:47:51Zdc.date.updated
VersionpublishedVersiondc.description.version
DOIhttp://dx.doi.org/10.18725/OPARU-43481dc.identifier.doi
URNhttp://nbn-resolving.de/urn:nbn:de:bsz:289-oparu-43557-4dc.identifier.urn
GNDKeuchhusten-Toxindc.subject.gnd
GNDChaperoninedc.subject.gnd
GNDDefensinedc.subject.gnd
InstitutionUKU. Institut für Pharmakologie und Toxikologieuulm.affiliationSpecific
Peer reviewjauulm.peerReview
DCMI TypeTextuulm.typeDCMI
CategoryPublikationenuulm.category
DOI of original publication10.3390/toxins14030187dc.relation1.doi
Source - Title of sourceToxinssource.title
Source - Place of publicationMDPIsource.publisher
Source - Volume14source.volume
Source - Issue3source.issue
Source - Year2022source.year
Source - Article number187source.articleNumber
Source - eISSN2072-6651source.identifier.eissn
Open AccessGreen Published, golduulm.OA
WoS000774519000001uulm.identifier.wos
Bibliographyuulmuulm.bibliographie
DFG project uulmSFB 1279 Teilprojekt A07 / Mechanismus und Struktur von Peptidfibrillen, die Virusinfektionen beeinflussen / DFG / 316249678uulm.projectDFG
Project uulmMargarete von Wrangell-Programm / MWK Baden-Württemberg, Universität Ulmuulm.projectOther


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record